These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 35618703)

  • 21. Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies.
    Bruel T; Stéfic K; Nguyen Y; Toniutti D; Staropoli I; Porrot F; Guivel-Benhassine F; Bolland WH; Planas D; Hadjadj J; Handala L; Planchais C; Prot M; Simon-Lorière E; André E; Baele G; Cuypers L; Mouthon L; Mouquet H; Buchrieser J; Sève A; Prazuck T; Maes P; Terrier B; Hocqueloux L; Schwartz O
    Cell Rep Med; 2022 Dec; 3(12):100850. PubMed ID: 36450283
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neutralizing Immunity Against Antigenically Advanced Omicron BA.5 in Children After SARS-CoV-2 Infection.
    Belongia EA; Petrie JG; Feldstein LR; Guan L; Halfmann PJ; King JP; Neumann G; Pattinson D; Rolfes MA; McLean HQ; Kawaoka Y
    J Pediatric Infect Dis Soc; 2024 Jan; 13(1):100-104. PubMed ID: 38142128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of antibody responses against SARS-CoV-2 in unvaccinated individuals and vaccinees from Omicron-BA.2 infection in Zhaoqing, Guangdong Province, China.
    Zhang H; Jiang Y; Tan H; Zou L; Zheng Z; Huang Y; Lin S; Su L; Yu J; Deng X; He J; Liu C; Shen C; Li B
    Virol J; 2022 Nov; 19(1):197. PubMed ID: 36434614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pathogenicity of SARS-CoV-2 Omicron (R346K) variant in Syrian hamsters and its cross-neutralization with different variants of concern.
    Mohandas S; Yadav PD; Sapkal G; Shete AM; Deshpande G; Nyayanit DA; Patil D; Kadam M; Kumar A; Mote C; Jain R
    EBioMedicine; 2022 May; 79():103997. PubMed ID: 35405385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. mRNA bivalent booster enhances neutralization against BA.2.75.2 and BQ.1.1.
    Davis-Gardner ME; Lai L; Wali B; Samaha H; Solis D; Lee M; Porter-Morrison A; Hentenaar IT; Yamamoto F; Godbole S; Douek DC; Lee FE; Rouphael N; Moreno A; Pinsky BA; Suthar MS
    bioRxiv; 2022 Nov; ():. PubMed ID: 36380757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Editorial: World Health Organization (WHO) Variants of Concern Lineages Under Monitoring (VOC-LUM) in Response to the Global Spread of Lineages and Sublineages of Omicron, or B.1.1.529, SARS-CoV-2.
    Parums DV
    Med Sci Monit; 2022 Jul; 28():e937676. PubMed ID: 35775166
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The viral fitness and intrinsic pathogenicity of dominant SARS-CoV-2 Omicron sublineages BA.1, BA.2, and BA.5.
    Shuai H; Chan JF; Hu B; Chai Y; Yoon C; Liu H; Liu Y; Shi J; Zhu T; Hu JC; Hu YF; Hou Y; Huang X; Yuen TT; Wang Y; Zhang J; Xia Y; Chen LL; Cai JP; Zhang AJ; Yuan S; Zhou J; Zhang BZ; Huang JD; Yuen KY; To KK; Chu H
    EBioMedicine; 2023 Sep; 95():104753. PubMed ID: 37579626
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
    Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SARS-CoV-2 genetic diversity: Its impact on vaccine efficacy.
    Lina B; Bauer J
    Infect Dis Now; 2022 Nov; 52(8S):S2-S3. PubMed ID: 36108974
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants.
    Liu J; Liu Y; Xia H; Zou J; Weaver SC; Swanson KA; Cai H; Cutler M; Cooper D; Muik A; Jansen KU; Sahin U; Xie X; Dormitzer PR; Shi PY
    Nature; 2021 Aug; 596(7871):273-275. PubMed ID: 34111888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extraordinary Titer and Broad Anti-SARS-CoV-2 Neutralization Induced by Stabilized RBD Nanoparticles from Strain BA.5.
    Wang Z; Zhang B; Ou L; Qiu Q; Wang L; Bylund T; Kong WP; Shi W; Tsybovsky Y; Wu L; Zhou Q; Chaudhary R; Choe M; Dickey TH; El Anbari M; Olia AS; Rawi R; Teng IT; Wang D; Wang S; Tolia NH; Zhou T; Kwong PD
    Vaccines (Basel); 2023 Dec; 12(1):. PubMed ID: 38250850
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5.
    Tartof SY; Slezak JM; Puzniak L; Hong V; Frankland TB; Ackerson BK; Takhar H; Ogun OA; Simmons S; Zamparo JM; Jodar L; McLaughlin JM
    Lancet Infect Dis; 2022 Dec; 22(12):1663-1665. PubMed ID: 36306800
    [No Abstract]   [Full Text] [Related]  

  • 33. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization.
    Planas D; Saunders N; Maes P; Guivel-Benhassine F; Planchais C; Buchrieser J; Bolland WH; Porrot F; Staropoli I; Lemoine F; Péré H; Veyer D; Puech J; Rodary J; Baele G; Dellicour S; Raymenants J; Gorissen S; Geenen C; Vanmechelen B; Wawina-Bokalanga T; Martí-Carreras J; Cuypers L; Sève A; Hocqueloux L; Prazuck T; Rey FA; Simon-Loriere E; Bruel T; Mouquet H; André E; Schwartz O
    Nature; 2022 Feb; 602(7898):671-675. PubMed ID: 35016199
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Homotypic and heterotypic immune responses to Omicron variant in immunocompromised patients in diverse clinical settings.
    Ferreira VH; Solera JT; Hu Q; Hall VG; Arbol BG; Rod Hardy W; Samson R; Marinelli T; Ierullo M; Virk AK; Kurtesi A; Mavandadnejad F; Majchrzak-Kita B; Kulasingam V; Gingras AC; Kumar D; Humar A
    Nat Commun; 2022 Aug; 13(1):4489. PubMed ID: 35927279
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Steep Decline in Binding Capability of SARS-CoV-2 Omicron Variant (B.1.1.529) RBD to the Antibodies in Early COVID-19 Convalescent Sera and Inactivated Vaccine Sera.
    Zhou W; He P; Li J; Liu H; Shi M; Yu J; Wei H
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Convolutional Neural Networks Based on Sequential Spike Predict the High Human Adaptation of SARS-CoV-2 Omicron Variants.
    Nan BG; Zhang S; Li YC; Kang XP; Chen YH; Li L; Jiang T; Li J
    Viruses; 2022 May; 14(5):. PubMed ID: 35632811
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analytical sensitivity of the Rapid Antigen Test kits for detection of SARS-CoV-2 Omicron variant BA.2 sublineage.
    Mak GCK; Lau SSY; Wong KKY; Lau CS; Ng KHL; Lam ETK; Chan RCW
    J Med Virol; 2022 Oct; 94(10):5033-5037. PubMed ID: 35656593
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine.
    Furukawa K; Tjan LH; Kurahashi Y; Sutandhio S; Nishimura M; Arii J; Mori Y
    JAMA Netw Open; 2022 May; 5(5):e2210780. PubMed ID: 35532938
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
    Choi A; Koch M; Wu K; Dixon G; Oestreicher J; Legault H; Stewart-Jones GBE; Colpitts T; Pajon R; Bennett H; Carfi A; Edwards DK
    J Virol; 2021 Nov; 95(23):e0131321. PubMed ID: 34549975
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low neutralization capacity against SARS-CoV-2 Omicron BQ.1.1 of convalescent plasma collected during circulation of Omicron BA.1.
    Gallian P; Brisbarre N; Nurtop E; Le Cam S; Franck T; Isnard C; Malard L; Laperche S; Richard P; Morel P; Tiberghien P; de Lamballerie X
    Vox Sang; 2023 May; 118(5):407-408. PubMed ID: 36897221
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.